Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto

Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto

The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gately, Maurice Kent, Gubler, Ulrich Andreas, Hulmes, Jeffrey David, Podlaski, Frank John, Stern, Alvin Seth, Chizzonite, Richard Anthony, Pan, Yu-Ching Eugene
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Gately, Maurice Kent
Gubler, Ulrich Andreas
Hulmes, Jeffrey David
Podlaski, Frank John
Stern, Alvin Seth
Chizzonite, Richard Anthony
Pan, Yu-Ching Eugene
description The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth.Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_08110187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>08110187</sourcerecordid><originalsourceid>FETCH-uspatents_grants_081101873</originalsourceid><addsrcrecordid>eNqNizEOwjAMRbswIOAOvgBSKwa6IxAjAzsyqUMtJXHlOBLl9BTKAZie3tf7yypeirJnh8aSAFMHrkdFZ6T8mkfx4EYTkyc7CGMcepmcIKIVnRM_HUS_9yhJXJCEYVLju3RMGawnJZN1tfAYMm1-XFVwOl4P523JAxoly7eH4gd12zR10-53fyRv_jVErw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto</title><source>USPTO Issued Patents</source><creator>Gately, Maurice Kent ; Gubler, Ulrich Andreas ; Hulmes, Jeffrey David ; Podlaski, Frank John ; Stern, Alvin Seth ; Chizzonite, Richard Anthony ; Pan, Yu-Ching Eugene</creator><creatorcontrib>Gately, Maurice Kent ; Gubler, Ulrich Andreas ; Hulmes, Jeffrey David ; Podlaski, Frank John ; Stern, Alvin Seth ; Chizzonite, Richard Anthony ; Pan, Yu-Ching Eugene ; Hoffman-La Roche Inc</creatorcontrib><description>The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth.Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.</description><language>eng</language><creationdate>2012</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8110187$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,780,802,885,64039</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8110187$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Gately, Maurice Kent</creatorcontrib><creatorcontrib>Gubler, Ulrich Andreas</creatorcontrib><creatorcontrib>Hulmes, Jeffrey David</creatorcontrib><creatorcontrib>Podlaski, Frank John</creatorcontrib><creatorcontrib>Stern, Alvin Seth</creatorcontrib><creatorcontrib>Chizzonite, Richard Anthony</creatorcontrib><creatorcontrib>Pan, Yu-Ching Eugene</creatorcontrib><creatorcontrib>Hoffman-La Roche Inc</creatorcontrib><title>Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto</title><description>The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth.Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2012</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNqNizEOwjAMRbswIOAOvgBSKwa6IxAjAzsyqUMtJXHlOBLl9BTKAZie3tf7yypeirJnh8aSAFMHrkdFZ6T8mkfx4EYTkyc7CGMcepmcIKIVnRM_HUS_9yhJXJCEYVLju3RMGawnJZN1tfAYMm1-XFVwOl4P523JAxoly7eH4gd12zR10-53fyRv_jVErw</recordid><startdate>20120207</startdate><enddate>20120207</enddate><creator>Gately, Maurice Kent</creator><creator>Gubler, Ulrich Andreas</creator><creator>Hulmes, Jeffrey David</creator><creator>Podlaski, Frank John</creator><creator>Stern, Alvin Seth</creator><creator>Chizzonite, Richard Anthony</creator><creator>Pan, Yu-Ching Eugene</creator><scope>EFH</scope></search><sort><creationdate>20120207</creationdate><title>Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto</title><author>Gately, Maurice Kent ; Gubler, Ulrich Andreas ; Hulmes, Jeffrey David ; Podlaski, Frank John ; Stern, Alvin Seth ; Chizzonite, Richard Anthony ; Pan, Yu-Ching Eugene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_081101873</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Gately, Maurice Kent</creatorcontrib><creatorcontrib>Gubler, Ulrich Andreas</creatorcontrib><creatorcontrib>Hulmes, Jeffrey David</creatorcontrib><creatorcontrib>Podlaski, Frank John</creatorcontrib><creatorcontrib>Stern, Alvin Seth</creatorcontrib><creatorcontrib>Chizzonite, Richard Anthony</creatorcontrib><creatorcontrib>Pan, Yu-Ching Eugene</creatorcontrib><creatorcontrib>Hoffman-La Roche Inc</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Gately, Maurice Kent</au><au>Gubler, Ulrich Andreas</au><au>Hulmes, Jeffrey David</au><au>Podlaski, Frank John</au><au>Stern, Alvin Seth</au><au>Chizzonite, Richard Anthony</au><au>Pan, Yu-Ching Eugene</au><aucorp>Hoffman-La Roche Inc</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto</title><date>2012-02-07</date><risdate>2012</risdate><abstract>The present invention is a novel cytokine protein called IL-12 or Cytotoxic Lymphocyte Maturation Factor (CLMF) which is produced and synthesized by human NC-37 B lymphoblastoid cells (American Type Culture Collection, Rockville, Md.). CLMF synergistically induces with low concentrations of IL-2 the cytolytic activity of Lymphokine Activated Killer (LAK) cells, and CLMF is capable of stimulating T-cell growth.Also claimed are the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by the transformed cells and antibodies to CLMF.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_08110187
source USPTO Issued Patents
title Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A27%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Gately,%20Maurice%20Kent&rft.aucorp=Hoffman-La%20Roche%20Inc&rft.date=2012-02-07&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E08110187%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true